Business
Ainos Reports Second Quarter 2024 Financial Results
Enrolling first subject for FCGS clinical study marks a solid start in shifting animal health emphasis to drug developmentsRobust financial runway for over 12
About this update from Ainos, Inc.
[{"type":"text","content":"Enrolling first subject for FCGS clinical study marks a solid start in shifting animal health emphasis to drug developmentsRobust financial runway for over 12 months following the prepayment of a senior secured convertible noteSAN DIEGO, CA / ACCESSWIRE / August 5, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) (\"Ainos\", or the \"Company\"), a diversified healthcare company focused on novel AI-powered point-of-care testing (\"POCT\") and low-dose interferon therapeutics (\"VELDONA®\"), today announced its financial results for the second quarter ended June 30, 2024.Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, \"We've made meaningful progress in initiating a clinical study for treating feline chronic gingivostomatitis (\"FCGS\"). This new animal drug potentially expands VELDONA®'s market. Our core strategy for this oral low-dose interferon alpha (IFNα) formulation remains focused on fast-tracking VELDONA® commercialization by identifying optimal opportunities and effectively utilizing our resources.\"\"Pets are becoming increasingly important to families. There is a rapidly growing trend of pet owners prioritizing animal health, and we are capitalizing on this by initially launching VELDONA® Pet supplements in Taiwan at the end of Q3 2023. Pet dogs and cats now outnumber children under 14 years old in Taiwan, making it an ideal trial market. Although VELDONA® Pet's sales have room for growth, we have gained valuable insights into demand: consumers favor health-enhancing food over standalone supplements in the current inflationary environment, and our Soothing and Alpha products, which address allergies and gum health respectively, have been particularly well-received among the five VELDONA® Pet products. These insights will shape our development strategy as drug becomes our emphasis for animal health market. I see significant market opportunity in FCGS, a cat oral disease with 0.7-10% estimated prevalence rate, where pet parents are facing few treatment options.\"\"VELDONA® has built a solid foundation in animal health since its 1985 approval for feline leukemia and canine parvovirus from the Texas Department of Health. Across 28 studies for a range of animal diseases, results have shown systemic benefits across a variety of animal species and a strong safety profile. A 202...